Analyst Derek Archila of Wells Fargo maintained a Buy rating on Rhythm Pharmaceuticals, retaining the price target of $129.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Derek Archila has given his Buy rating due to a combination of factors that highlight the growth potential and strategic advancements of Rhythm Pharmaceuticals. The company’s recent earnings report showed a solid performance, with IMCIVREE revenues surpassing expectations, indicating strong growth in both the U.S. and international markets, particularly among patients accessing early programs. This revenue beat is a positive sign for continued expansion, especially in the BBS and HO segments.
Additionally, the upcoming catalysts such as the POC in PWS and the IMCIVREE sNDA filing for HO further support the Buy rating. The management’s productive meeting with the FDA and the anticipated approval of IMCIVREE for new indications reduce regulatory risks. Furthermore, the potential for franchise extension with biva in HO and the expected data for RM-718 in 2026 present additional opportunities for revenue growth. These factors, combined with the stock’s current undervaluation relative to its growth prospects, underpin Archila’s positive outlook on Rhythm Pharmaceuticals.
In another report released today, Guggenheim also maintained a Buy rating on the stock with a $120.00 price target.